Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...
Ophthalmology Times

Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Stopping GLP-1 drugs like Ozempic erodes heart health benefits quickly, new study finds

Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular ...

Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
The Manila Times

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% ...